tetano
Editor, Senior Moderator
Sci Rep
. 2024 Oct 18;14(1):24420.
doi: 10.1038/s41598-024-75250-2. Similar humoral responses but distinct CD4[SUP]+[/SUP] T cell transcriptomic profiles in older adults elicited by MF59 adjuvanted and high dose influenza vaccines
Huy Quang Quach[SUP] 1 [/SUP], Iana H Haralambieva[SUP] 1 [/SUP], Krista M Goergen[SUP] 2 [/SUP], Diane E Grill[SUP] 2 [/SUP], Jun Chen[SUP] 2 [/SUP], Inna G Ovsyannikova[SUP] 1 [/SUP], Gregory A Poland[SUP] 1 [/SUP], Richard B Kennedy[SUP] 3 [/SUP]
Affiliations
Older age (≥ 65 years) is associated with impaired responses to influenza vaccination, leading to the preferential recommendation of MF59-adjuvanted (MF59Flu) or high-dose (HDFlu) influenza vaccines for this age group in the United States. Herein, we characterized transcriptomic profiles of CD4[SUP]+[/SUP] T cells isolated from 234 recipients (≥ 65 years) of either MF59Flu or HDFlu vaccine, prior to vaccination and 28 days thereafter. We identified 412 and 645 differentially expressed genes (DEGs) in CD4[SUP]+[/SUP] T cells of older adults after receiving MF59Flu and HDFlu, respectively. DEGs in CD4[SUP]+[/SUP] T cells of MF59Flu recipients were enriched in 14 KEGG pathways, all of which were downregulated. DEGs in CD4[SUP]+[/SUP] T cells of HDFlu recipients were enriched in 11 upregulated pathways and 20 downregulated pathways. CD4[SUP]+[/SUP] T cells in both vaccine groups shared 50 upregulated genes and 75 downregulated genes, all of which were enriched in 7 KEGG pathways. The remaining 287 and 520 DEGs were specifically associated with MF59Flu and HDFlu, respectively. Unexpectedly, none of these DEGs was significantly correlated with influenza A/H3N2-specific HAI titers, suggesting these DEGs at the individual level may have a limited role in protection against influenza. Our findings emphasize the need for further investigation into other factors influencing immunity against influenza in older adults.
Keywords: CD4+ T cells; Gene expression profiling; High-dose influenza vaccine; MF59-adjuvanted influenza vaccine; Older adults.
. 2024 Oct 18;14(1):24420.
doi: 10.1038/s41598-024-75250-2. Similar humoral responses but distinct CD4[SUP]+[/SUP] T cell transcriptomic profiles in older adults elicited by MF59 adjuvanted and high dose influenza vaccines
Huy Quang Quach[SUP] 1 [/SUP], Iana H Haralambieva[SUP] 1 [/SUP], Krista M Goergen[SUP] 2 [/SUP], Diane E Grill[SUP] 2 [/SUP], Jun Chen[SUP] 2 [/SUP], Inna G Ovsyannikova[SUP] 1 [/SUP], Gregory A Poland[SUP] 1 [/SUP], Richard B Kennedy[SUP] 3 [/SUP]
Affiliations
- PMID: 39424894
- PMCID: PMC11489691
- DOI: 10.1038/s41598-024-75250-2
Older age (≥ 65 years) is associated with impaired responses to influenza vaccination, leading to the preferential recommendation of MF59-adjuvanted (MF59Flu) or high-dose (HDFlu) influenza vaccines for this age group in the United States. Herein, we characterized transcriptomic profiles of CD4[SUP]+[/SUP] T cells isolated from 234 recipients (≥ 65 years) of either MF59Flu or HDFlu vaccine, prior to vaccination and 28 days thereafter. We identified 412 and 645 differentially expressed genes (DEGs) in CD4[SUP]+[/SUP] T cells of older adults after receiving MF59Flu and HDFlu, respectively. DEGs in CD4[SUP]+[/SUP] T cells of MF59Flu recipients were enriched in 14 KEGG pathways, all of which were downregulated. DEGs in CD4[SUP]+[/SUP] T cells of HDFlu recipients were enriched in 11 upregulated pathways and 20 downregulated pathways. CD4[SUP]+[/SUP] T cells in both vaccine groups shared 50 upregulated genes and 75 downregulated genes, all of which were enriched in 7 KEGG pathways. The remaining 287 and 520 DEGs were specifically associated with MF59Flu and HDFlu, respectively. Unexpectedly, none of these DEGs was significantly correlated with influenza A/H3N2-specific HAI titers, suggesting these DEGs at the individual level may have a limited role in protection against influenza. Our findings emphasize the need for further investigation into other factors influencing immunity against influenza in older adults.
Keywords: CD4+ T cells; Gene expression profiling; High-dose influenza vaccine; MF59-adjuvanted influenza vaccine; Older adults.